188559-10-6

Basic information

• Product Name: (4R)-3-[(2S,3S)-2-Acetyl-3-[3-[bis(phenylmethyl)amino]phenyl]-1-oxopentyl]-4-phenyl-2-oxazolidinone
• Synonyms: (4R)-3-[(2S,3S)-2-Acetyl-3-[3-[bis(phenylmethyl)amino]phenyl]-1-oxopentyl]-4-phenyl-2-oxazolidinone;[4R-[3(2S*,3S*),4R*]]-3-[2-Acetyl-3-[3-[bis(phenylmethyl)amino]phenyl]-1-oxopentyl]-4-phenyl-2-oxazolidinone
• CAS NO: 188559-10-6
• Molecular Formula: C₃₆H₃₆N₂O₄
• Molecular Weight: 560.27
• Product Categories: Chemical Amines;Amines;Aromatics;Chiral Reagents;Heterocycles
• Mol File: 188559-10-6.mol

Chemical Properties

• Boiling Point: 752.933 °C at 760 mmHg
• Flash Point: 409.159 °C
• Appearance: /
• Density: 1.209 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.624
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• CAS DataBase Reference: (4R)-3-[(2S,3S)-2-Acetyl-3-[3-[bis(phenylmethyl)amino]phenyl]-1-oxopentyl]-4-phenyl-2-oxazolidinone(CAS DataBase Reference)
• NIST Chemistry Reference: (4R)-3-[(2S,3S)-2-Acetyl-3-[3-[bis(phenylmethyl)amino]phenyl]-1-oxopentyl]-4-phenyl-2-oxazolidinone(188559-10-6)
• EPA Substance Registry System: (4R)-3-[(2S,3S)-2-Acetyl-3-[3-[bis(phenylmethyl)amino]phenyl]-1-oxopentyl]-4-phenyl-2-oxazolidinone(188559-10-6)

Safety Data

• Hazardous Substances Data: 188559-10-6(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Foam

InChI:InChI=1/C36H36N2O4/c1-3-32(34(26(2)39)35(40)38-33(25-42-36(38)41)29-18-11-6-12-19-29)30-20-13-21-31(22-30)37(23-27-14-7-4-8-15-27)24-28-16-9-5-10-17-28/h4-22,32-34H,3,23-25H2,1-2H3/t32-,33+,34-/m1/s1

Upstream product

• 75-36-5 acetyl chloride 
• 174590-40-0 (R)-3-[(S)-3-(3-Dibenzylamino-phenyl)-pentanoyl]-4-phenyl-oxazolidin-2-one 
• 188559-05-9 (R)-N-[(E)-EtCHCHC(O)]-4-phenyl-1,3-oxazolidin-2-one 
• 90319-52-1 (4R)-phenyl-2-oxazolidinone 
• 33698-85-0 (E)-pent-2-enoyl chloride 
• 19798-71-1 2-methyl-2-methoxy-1,3-dioxolane 

Downstream Products

• 188559-25-3 (R)-3-[(R)-1-(3-Dibenzylamino-phenyl)-propyl]-4-hydroxy-6-phenethyl-6-prop-1-ynyl-5,6-dihydro-pyran-2-one 
• 174485-53-1 3-[(R)-1-(3-Dibenzylamino-phenyl)-propyl]-4-hydroxy-6,6-dipropyl-5,6-dihydro-pyran-2-one 
• 174485-90-6 (R)-3-[(R)-1-(3-Amino-phenyl)-propyl]-4-hydroxy-6-phenethyl-6-propyl-5,6-dihydro-pyran-2-one 
• 174485-54-2 <3α(R)>-3-<1-(3-aminophenyl)propyl>-5,6-dihydro-6,6-dipropyl-4-hydroxy-2H-pyran-2-one 
• 174484-41-4 tipranavir 
• 188559-22-0 (2S,5R)-2-[(S)-1-(3-Dibenzylamino-phenyl)-propyl]-5-hydroxy-1-((R)-2-oxo-4-phenyl-oxazolidin-3-yl)-5-phenethyl-oct-6-yne-1,3-dione 
• 188559-16-2 (2S,5R)-2-[(S)-1-(3-Dibenzylamino-phenyl)-propyl]-5-hydroxy-1-((R)-2-oxo-4-phenyl-oxazolidin-3-yl)-5-phenethyl-octane-1,3-dione 
• 188559-14-0 (S)-2-[(S)-1-(3-Dibenzylamino-phenyl)-propyl]-5-hydroxy-1-((R)-2-oxo-4-phenyl-oxazolidin-3-yl)-5-propyl-octane-1,3-dione 

Relevant articles and documents

PROTEASE INHIBITORS HAVING ENHANCED FEATURES

Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.